



Poster Note PN-16

Rapid Detection of Deamidation in Monoclonal Antibodies using Ultrahigh-Resolution QTOF Mass Spectrometry

Introduction

Characterizing the heterogeneity occurring in therapeutic antibodies (mAbs) is a fundamental task of all product development and commercialization phases. Asn deamidation is a particularly important source of heterogeneity, however challenging to detect on intact proteins given the +0.984 Da mass addition, and currently is characterized with bottom-up approaches. As proteolytic digests take considerable time and can introduce additional method-related deamidation, we developed a rapid method that utilizes middle-up antibody fragment isotopic distributions to detect, identify, and profile the degree of antibody deamidation while minimizing risks of artificial deamidation. The method was developed and tested on a model system for deamidation and then applied to a partially deamidated antibody light chain (LC).

Authors

W. Jabs, W. Evers, A. Wiechmann, D. Suckau
Bruker Corporation, Bremen, Germany

J. Wood
Bruker Corporation, Billerica, MA, USA

G. Tremintin
Bruker Daltonics, Fremont, CA, USA

K. Johnson, H. DeGruttola, L. Marzilli, J. Rouse
Pfizer, Andover, MA, USA

Keywords	Instrumentation and Software
Biologics	maxis II
Deamidation	BioPharma Compass 1.1.
Quantification	
UHR-QTOF	
Process Development	
mAb	
monoclonal antibody	
clone selection	

Methods

A model system for deamidation of biologics was generated in the following way:
Adalimumab (Abbvie) was partially reduced with DTT – only interchain disulfide bonds are cleaved.

- Sample was split into two aliquots – one aliquot alkylated with iodoacetamide (IAM) the other with iodoacetic acid (IAA).
- The LC of the two aliquots (LC-IAM and LC-IAA) differ by 1 Da thus modeling deamidation. LC-IAM represents the unmodified form, LC-IAA, the deamidated protein.
- LC-IAM : LC-IAA were mixed in different ratios:
 - 95:5, 90:10, 75:25, 60:40 and 50:50
 - and compared to the pure aliquots.
- LC-MS was performed using standard reverse-phase chromatography coupled to a maXis II UHR Q-TOF (Bruker) providing 80,000 resolution and isotopic resolution of light and heavy chains.
- Automated data processing with Biopharma Compass included MS raw spectrum generation, followed by Maximum Entropy deconvolution and monoisotopic peak picking using the SNAP algorithm (Bruker).

Characterization of the model system




Figure 1: Overlaid TICs from 3 different samples. The amount on column of LC-IAM and LC-IAA in the mixture and in the pure samples are the same (A). (B-D) show the derived Max. Ent. spectra and the comparison to the expected isotopic pattern of LC-IAM.

Validation of the deamidation detection tool




Figure 2: Overlaid TICs from the 95:5 mixture and pure LC-IAA in the same amount as contained in the mixture (A). Two spectra acquired at different R times are shown and compared to the expected isotopic pattern of LC-IAM (B, C): green. While spectrum 1 shows a perfect match (B), spectrum 2 shows a + 1Da mass shift indicating the presence of the deamidated species (C); The M_r of LC-IAA is determined in spectrum 2 as well.

Results

- Fig. 1 shows the total ion chromatogram (TIC) for mixing ratio LC-IAM:LC-IAA 95:5 together with the TICs of the pure samples constraining the same amount of LC-IAM and LC-IAA as the mixture (A). The derived spectra are compared to the expected isotopic pattern of LC-IAM. The pure LC-IAM spectrum results in a perfect match (B), the 95% mixture shows small deviations (C), while a clear +1 Da shift is apparent for pure LC-IAA (D).
- The mass of the most abundant species in the TIC compound spectra is reliably detected with mass accuracy of 1 ppm and better.
- The new method for rapid deamidation detection on middle-up level makes use of the small retention time shift (Fig. 1) and the reliable detection of the dominant species: For each MS spectrum of the chromatographic peak the Mr is calculated. If a 1 Da mass shift is observed an evidence for deamidation is reported. The intensities of the MS spectra are used for profiling.
- Fig. 2 compares two spectra of different retention times (RT) for the 95:5 mixture (A). During elution the isotopic pattern and the determined Mr changes (B, C).
- Tab. 1 and Fig. 3 summarizes the application of the method to all samples of the model system with LC-IAM:LC-IAA ratios from 50 : 50 to 100 : 0. The pure LC-IAM samples do not show changes in Mr as indicated in the "Deamid. Evidence" column. For all mixtures in the study the deamidation percentage was reliably determined.
- The "Deamid. Percentage" derived from the intensities of the deconv. MS spectra overestimates the content of LC-IAA, probably due to chromatographic saturation effects. However, it is a good semi-quantitative measure of the impurity amount (Fig. 2).
- Fig. 4 displays the automatically generated report indicating detection of deamidation, while Fig. 5 shows the application of the method to a partially deamidated LC of a mAb.

Mixing Ratio LC-IAM : LC-IAA	Deamid. Evidence	Deamid. Percent. / %
pure LC-IAM	FALSE	0
95 : 5	TRUE	17
90 : 10	TRUE	26
75 : 25	TRUE	40
60 : 40	TRUE	51
50 : 50	TRUE	63




Table 1 and Figure 3: Result of the automated processing of different mixing ratios compared to the pure sample. Deamidations percentage are reliably detected.

Automated deamidation report in BioPharma Compass


Compound MS Peak Lists

Compound Name	ID	Mr (Ana.)	Mr (Ref)	Delta Mr [ppm]	Deamid. Evid.	Deamid. Perc. [%]
Cmpd 1; 32.0 min						
Cmpd 1; 32.0 min	LC-IAM	23450.5780	23450.5994	-0.91	True	17


Figure 4: Excerpt from the report for the 95:5 mixture which is automatically generated under BioPharma Compass, indicating that deamidation was observable and its percentage.

Detection of deamidation of an antibody Light Chain


Bulk Material
Deamidation: 9%



Main CEX-HPLC Fraction
Deamidation: 1%



Acidic CEX-HPLC Fraction
Deamidation: 40%



Acidic CEX-HPLC Fraction LC Spectra




Figure 5: Application of the new method to an mAb LC with deamidation. Using only RP-HPLC a deamidation of 9% was detected. This was confirmed by cation exchange chromatography (CEX). Running HPLC on the main and on the acidic CEX fraction resulted in detection of a 40% deamidation and an observable R_t shift in the acidic fraction.

Conclusion

- Latest UHR-QTOF technology allows for determination of monoisotopic masses of antibody subunits with accuracies of 1 ppm and better with precisely matching isotope patterns.
- The new Middle-Up deamidation detection method determines the M_r of the isotopic peak pattern across the chromatographic peak. A change in M_r caused by deamidation is reported and quantified.
- Mixing ratios up to 95:5 were reliably and automatically detected for the deamidation model system and successfully applied to a deamidated mAb.

For research use only. Not for use in diagnostic procedures.

● Bruker Daltonik GmbH

Bremen · Germany
Phone +49 (0)421-2205-0
Fax +49 (0)421-2205-103

Bruker Daltonics Inc.

Billerica, MA · USA
Phone +1 (978) 663-3660
Fax +1 (978) 667-5993

ms.sales.bdal@bruker.com - www.bruker.com